Insider Buying: Organogenesis Holdings Inc. (NASDAQ:ORGO) Insider Buys 142,379 Shares of Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) insider Lori Freedman bought 142,379 shares of the firm's stock in a transaction on Thursday, June 5th. The shares were purchased at an average price of $2.91 per share, for a total transaction of $414,322.89. Following the purchase, the insider now owns 837,437 shares in the company, valued at $2,436,941.67. This trade represents a 20.48% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Lori Freedman also recently made the following trade(s):

• On Friday, June 6th, Lori Freedman purchased 9,022 shares of Organogenesis stock. The shares were acquired at an average cost of $2.99 per share, for a total transaction of $26,975.78.
• On Wednesday, June 4th, Lori Freedman purchased 100,863 shares of Organogenesis stock. The stock was bought at an average price of $2.82 per share, for a total transaction of $284,433.66.

Organogenesis Trading Up 5.2%

Organogenesis stock traded up $0.15 during mid-day trading on Friday, hitting $3.03. The company's stock had a trading volume of 991,674 shares, compared to its average volume of 1,145,660. The stock has a market cap of $384.37 million, a PE ratio of -50.50 and a beta of 1.85. Organogenesis Holdings Inc. has a one year low of $2.28 and a one year high of $6.71. The company has a 50 day moving average of $3.85 and a 200-day moving average of $3.86. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The firm had revenue of $86.69 million during the quarter, compared to the consensus estimate of $90.77 million. On average, research analysts anticipate that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Analysts Set New Price Targets

Separately, Morgan Stanley lifted their price objective on shares of Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a research note on Wednesday, March 5th.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC grew its stake in Organogenesis by 10.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company's stock worth $187,000 after buying an additional 4,239 shares during the last quarter. CWM LLC lifted its position in Organogenesis by 8.9% during the first quarter. CWM LLC now owns 63,894 shares of the company's stock valued at $276,000 after purchasing an additional 5,239 shares during the period. Millennium Management LLC lifted its holdings in shares of Organogenesis by 2.8% in the 4th quarter. Millennium Management LLC now owns 208,420 shares of the company's stock valued at $667,000 after buying an additional 5,765 shares during the period. ProShare Advisors LLC increased its holdings in shares of Organogenesis by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock valued at $65,000 after purchasing an additional 6,689 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Organogenesis by 7.1% in the fourth quarter. Rhumbline Advisers now owns 115,266 shares of the company's stock worth $369,000 after acquiring an additional 7,621 shares during the period. 49.57% of the stock is owned by institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.